

CSL LTD.

ISIN: AU000000CSL8 WKN: CSL Asset Class: Stock

Company

2023/09/29 08:10:12



Price
250.80
AUD

Difference **-0.49%(-1.24)**



Contact Details

CSL LTD. Tel: +61-3-9389-1911
 -- Fax: +61-3-9389-1434
 655 Elizabeth Street Web: <http://www.csl.com.au>
 3000 Melbourne E-mail: media@csl.com.au

Company Profile

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

Financial figures, Fiscal year: from 01.07. to 30.06.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	13,909,712,000	-	23,937,613,000	-	9,843,090,000	-
Common stock capital						
Fixed assets	40,524,299,000		17,283,938,000		14,341,924,000	
Equity capital of a company		26,779,839,000		21,199,011,000		11,163,902,000
Cash and cash equivalents	2,325,546,000		15,176,906,000		2,409,324,000	
Accrued liabilities		1,008,037,000		422,744,000		525,074,000
Other assets	-		-		-	
Current liabilities		6,922,556,000		10,336,944,000		4,133,999,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		20,731,615,000		9,685,595,000		8,837,562,000
Different income		-		-		-
Other liabilities		740,629,000		779,030,000		596,869,000
Total assets	54,434,011,000	54,434,011,000	41,221,551,000	41,221,551,000	24,185,014,000	24,185,014,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	32,000	30,000	25,000
Equity ratio	54.83%	51.43%	46.16%
Debt-equity ratio	82.39%	94.45%	116.64%

Others

	2023	2022	2021
Tax Expense Rate	15.73%	18.88%	19.85%

CSL LTD.

ISIN: AU000000CSL8 WKN: CSL Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	19,585,285,000	14,469,426,000	13,761,477,000
Net income	3,336,069,000	3,109,111,000	3,183,882,000
EBIT	2,811,960,215	2,461,644,246	2,541,569,948
Operating income before taxes	3,958,980,000	3,832,920,000	3,972,278,000
Cash Flow	3,866,807,000	3,624,837,000	4,855,454,000
Net interest income	-694,271,000	-240,626,000	-233,529,000
Research and development expenses	1,836,027,000	1,594,338,000	1,342,458,000
Income taxes	622,911,000	723,809,000	788,396,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	369,856	291,462	332,642

Board of Directors

Brian McNamee	Chairman of Supervisory Board
Andrew Cuthbertson	Member of Supervisory Board
Duncan Maskell	Member of Supervisory Board
Megan Clark	Member of Supervisory Board
Alison Watkins	Member of Supervisory Board
Bruce Brook	Member of Supervisory Board
Carolyn Hewson	Member of Supervisory Board
Marie McDonald	Member of Supervisory Board

Members of Management Board

Paul Perreault	Chairman of Managing Board
Alan Wills	Member of Executive Committee
Bill Campbell	Member of Executive Committee
Bill Mezzanotte	Member of Executive Committee
Elizabeth Walker	Member of Executive Committee
Greg Boss	Member of Executive Committee
John Levy	Member of Executive Committee
Mark Hill	Member of Executive Committee
Paul McKenzie	Member of Executive Committee